trial

ACP-104 in Acutely Psychotic Subjects With Schizophrenia

NCTId NCT00490516
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 247 (actual)
Sponsored by ACADIA Pharmaceuticals Inc.
Primary completion 2008-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
247 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2007-06
Primary completion
2008-02
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
ACP-104

Sponsors

ACADIA Pharmaceuticals Inc.Lead Sponsor

Sites

0 total

Linked catalysts

1
ACP-104 in Acutely Psychotic Subjects With Schizophrenia — primary completion2008-02

Facts & assertions

4 sourced
Enrollment
247
Phase
PHASE2
Primary Completion Date
2008-02
Status
COMPLETED
relationships
The graph out of here
drug
ACP-104
drug
lead_sponsor
ACADIA Pharmaceuticals Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
Psychotic Disorders
indication